A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists

Article Sidebar

PDF HTML
Published: Mar 2, 2025
Keywords:
TB, NTM, pediatric TB, TBnet

Main Article Content

Christoph Lange
Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany; Clinical Tuberculosis Unit, German Center for Infection Research (DZIF), Hamburg-Lübeck- Borstel-Riems, Germany; Respiratory Medicine and International Health, University of Lübeck, Germany; Baylor College of Medicine and Texas Children´s Hospital, Global TB Program, Houston, Texas
Graham Bothamley
Homerton University Hospital, London, United Kingdom; Queen Mary University of London, London, United Kingdom; London School of Hygiene and Tropical Medicine, London, United Kingdom
Gunar Günther
Department of Pulmonology, Allergology and Clinical Immunology, Inselspital Bern, Bern University Hospital, Bern, Switzerland; Department of Clinical Sciences, School of Medicine, University of Namibia, Windhoek, Namibia
Lorenzo Guglielmetti
Sorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France; Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié -Salpetrière, Centre National de Reference des Mycobactéries et de la Resistance des Mycobactéries aux Antituberculeux, Paris, France
Irina Kontsevaya
Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom
Liga Kuksa
Tuberculosis and Lung Disease clinic, Riga East University hospital, Riga, Latvia
Berit Lange
Department of Epidemiology, Helmholtz Centre for Infection Research; German Center for Infection Research, TI BBD
Natalie Lorent
Department of Respiratory Diseases, University Hospital Leuven; Department of Chronic Diseases, Metabolism and Aging, Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), KU Leuven, Leuven, Belgium
Francesca Saluzzo
IRCCS San Raffaele Scientific Institute; Vita salute San Raffaele University, Milan, Italy
Martina Sester
Department of Transplant and Infection Immunology, Center for Gender-specific Biology and Medicine (CGBM), Saarland University, Homburg, Germany
Marc Tebruegge
Department of Child and Adolescent Medicine & Austrian National Reference Centre for Childhood Tuberculosis, Klinik Ottakring, Vienna Healthcare Group, Vienna, Austria; Infectious Diseases Network, Vienna Healthcare Group, Vienna, Austria; Department of Paediatrics, University of Melbourne, Parkville, Australia
Simone Tunesi
Infectious Diseases Unit, AOU SS Antonio e Biagio e C. Arrigo, Alessandria, Italy
Conor D. Tweed
MRC Clinical Trials Unit, University College London, London, United Kingdom

Abstract

Background: In the field of tuberculosis and non-tuberculous mycobacterial (NTM) disease we are looking back on an exciting year 2024 with more than 10,000 publications listed in PubMed.


Methods: Our aim, to review the scientific literature of the year 2024, is challenged by the enormous number of publications. Therefore, if your article is not included or your favorite field of mycobacteriology not covered, please forgive us. Our “Year in Review” is very much clinically oriented with lesser emphasis on basic science, microbiology, and biotechnology.


Results: Members of the steering committee of the Tuberculosis Network European Trials group (TBnet; www.tbnet.eu) report on 139 publications in the fields of epidemiology, prevention, diagnosis, and treatment of tuberculosis and NTM diseases published in 2024 that we found particularly important. We report publications separately for tuberculosis in children and adults and for NTM disease and provide a brief overview of newer technologies in the diagnostic pipeline. Furthermore, we summarize priorities for tuberculosis and NTM disease research, development, and implementation, all of which represent the perspective of our combined clinical experience.


Conclusions: This Year in Review provides a concise summary of the clinically relevant highlights of the published literature in tuberculosis and NTM diseases in 2024.

Downloads

Download data is not yet available.

Article Details

Issue
Vol. 10 No. 2 (2025): Volume 10, Number 2
Section
Reviews
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Pathogens and Immunity abides by Creative Commons BY 4.0:

http://creativecommons.org/licenses/by/4.0/

This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.

*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.   

References

1. World Health Organization. Global tuberculosis report 2024. Geneva Switzerland: 2024 Contract No.: CC BY-NC-SA 3.0 IGO.

2. Ratnatunga CN, Lutzky VP, Kupz A, Doolan DL, Reid DW, Field M, Bell SC, Thomson RM, Miles JJ. The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Front Immunol. 2020;11:303. doi: 10.3389/fimmu.2020.00303. PubMed PMID: 32194556; PMCID: PMC7062685.

3. Jarchow-MacDonald A, Smith M, Seagar AL, Russell CD, Claxton P, Laurenson IF, Moncayo-Nieto OL. Changing Incidence and Characteristics of Nontuberculous Mycobacterial Infections in Scotland and Comparison With Mycobacterium tuberculosis Complex Incidence (2011 to 2019). Open Forum Infect Dis. 2023;10(1):ofac665. doi: 10.1093/ofid/ofac665. PubMed PMID: 36726549; PMCID: PMC9879710.

4. Dahl VN, Pedersen AA, Norman A, Rasmussen EM, van Ingen J, Andersen AB, Wejse CM, Lillebaek T. Clinical Significance, Species Distribution, and Temporal Trends of Nontuberculous Mycobacteria, Denmark, 1991-2022. Emerg Infect Dis. 2024;30(9):1755-62. doi: 10.3201/eid3009.240095. PubMed PMID: 39173666; PMCID: PMC11346989.

5. Shaw ES, Stoker NG, Potter JL, Claassen H, Leslie A, Tweed CD, Chiang CY, Conradie F, Esmail H, Lange C, Pinto L, Rucsineanu O, Sloan DJ, Theron G, Tisile P, Voo TC, Warren RM, Lebina L, Lipman M. Bedaquiline: what might the future hold? Lancet Microbe. 2024;5(12):100909. doi: 10.1016/S2666-5247(24)00149-6. PubMed PMID: 39074472.

6. Cirillo D, Anthony R, Gagneux S, Horsburgh CR, Jr., Hasan R, Darboe S, Laniado-Laborin R, Probandari A, Tukvadze N, Arcencio RA, Bimba JS, Brighenti S, Chesov D, Chiang CY, Kalmambetova G, Knight G, Konstantynovska O, Kruse A, Lange C, Mayanja-Kizza H, McBryde E, Min J, Sanchez-Montalva A, Sulis G, Tsogt B, Van Der Walt M, Yeboah-Manu D, Hauser J. A successful UN High-Level Meeting on antimicrobial resistance must build on the 2023 UN High-Level Meeting on tuberculosis. Lancet Glob Health. 2024;12(8):e1225-e6. doi: 10.1016/S2214-109X(24)00229-8. PubMed PMID: 39030054.

7. Global Burden of Disease Tuberculosis Collaborators. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Infect Dis. 2024;24(7):698-725. doi: 10.1016/S1473-3099(24)00007-0. PubMed PMID: 38518787; PMCID: PMC11187709.

8. Ho CS, Wong CTH, Aung TT, Lakshminarayanan R, Mehta JS, Rauz S, McNally A, Kintses B, Peacock SJ, de la Fuente-Nunez C, Hancock REW, Ting DSJ. Antimicrobial resistance: a concise update. Lancet Microbe. 2024:100947. doi: 10.1016/j.lanmic.2024.07.010. PubMed PMID: 39305919.

9. Global burden of Disease Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. Lancet. 2024;404(10459):1199-226. doi: 10.1016/S0140-6736(24)01867-1. PubMed PMID: 39299261.

10. World Health Organization. WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva, Switzerland: 2024 Contract No.: CC BY-NC-SA 3.0 IGO.

11. Dahl VN, Butova T, Rosenthal A, Grinev A, Gabrielian A, Vashakidze S, Shubladze N, Toxanbayeva B, Chingissova L, Crudu V, Chesov D, Kalmambetova G, Saparova G, Wejse CM, Butov D, Ukraine TBPSG. Drug-Resistant Tuberculosis, Georgia, Kazakhstan, Kyrgyzstan, Moldova, and Ukraine, 2017-2022. Emerg Infect Dis. 2024;30(4):831-3. doi: 10.3201/eid3004.231732. PubMed PMID: 38526186; PMCID: PMC10977852.

12. Coussens AK, Zaidi SMA, Allwood BW, Dewan PK, Gray G, Kohli M, Kredo T, Marais BJ, Marks GB, Martinez L, Ruhwald M, Scriba TJ, Seddon JA, Tisile P, Warner DF, Wilkinson RJ, Esmail H, Houben R, International Consensus for Early TBg. Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise. Lancet Respir Med. 2024;12(6):484-98. doi: 10.1016/S2213-2600(24)00028-6. PubMed PMID: 38527485; PMCID: PMC7616323.

13. Churchyard GJ, Houben R, Fielding K, Fiore-Gartland AL, Esmail H, Grant AD, Rangaka MX, Behr M, Garcia-Basteiro AL, Wong EB, Hatherill M, Mave V, Dagnew AF, Schmidt AC, Hanekom WA, Cobelens F, White RG. Implications of subclinical tuberculosis for vaccine trial design and global effect. Lancet Microbe. 2024;5(10):100895. doi: 10.1016/S2666-5247(24)00127-7. PubMed PMID: 38964359; PMCID: PMC11464400.

14. Stuck L, Klinkenberg E, Abdelgadir Ali N, Basheir Abukaraig EA, Adusi-Poku Y, Alebachew Wagaw Z, Fatima R, Kapata N, Kapata-Chanda P, Kirenga B, Maama-Maime LB, Mfinanga SG, Moyo S, Mvusi L, Nandjebo N, Nguyen HV, Nguyen HB, Obasanya J, Adedapo Olufemi B, Patrobas Dashi P, Raleting Letsie TJ, Ruswa N, Rutebemberwa E, Senkoro M, Sivanna T, Yuda HC, Law I, Onozaki I, Tiemersma E, Cobelens F, sc TBMIG. Prevalence of subclinical pulmonary tuberculosis in adults in community settings: an individual participant data meta-analysis. Lancet Infect Dis. 2024;24(7):726-36. doi: 10.1016/S1473-3099(24)00011-2. PubMed PMID: 38490237.

15. Nordholm AC, Joergensen A, Holm LH, Andersen AB, Koch A, Andersen PH, Lillebaek T. The impact of living conditions and health interventions on tuberculosis, Denmark, 1876 to 2022. Euro Surveill. 2024;29(24). doi: 10.2807/1560-7917.ES.2024.29.24.2300652. PubMed PMID: 38873798; PMCID: PMC11177568.

16. Ciobanu A, Plesca V, Doltu S, Manea M, Domente L, Dadu A. TB and poverty: the effect of rifampicin-resistant TB on household income. IJTLD Open. 2024;1(4):181-8. doi: 10.5588/ijtldopen.23.0607. PubMed PMID: 38988411; PMCID: PMC11231822.

17. Argel M, Conde M, Vieira M, Lange C, Magis-Escurra C, Duarte R. Screening of refugees from Ukraine for TB: a TBnet survey. Int J Tuberc Lung Dis. 2024;28(4):202-3. doi: 10.5588/ijtld.23.0447. PubMed PMID: 38563334.

18. Kunst H, Lange B, Hovardovska O, Bockey A, Zenner D, Andersen AB, Hargreaves S, Pareek M, Friedland JS, Wejse C, Bothamley G, Guglielmetti L, Chesov D, Tiberi S, Matteelli A, Mandalakas AM, Heyckendorf J, Eimer J, Malhotra A, Zamora J, Vasiliu A, Lange C, Tbnet. Tuberculosis in adult migrants in Europe: a TBnet consensus statement. Eur Respir J. 2024. doi: 10.1183/13993003.01612-2024. PubMed PMID: 39672603.

19. Liu YE, Mabene Y, Camelo S, Rueda ZV, Pelissari DM, Dockhorn Costa Johansen F, Huaman MA, Avalos-Cruz T, Alarcon VA, Ladutke LM, Bergman M, Cohen T, Goldhaber-Fiebert JD, Croda J, Andrews JR. Mass incarceration as a driver of the tuberculosis epidemic in Latin America and projected effects of policy alternatives: a mathematical modelling study. Lancet Public Health. 2024;9(11):e841-e51. doi: 10.1016/S2468-2667(24)00192-0. PubMed PMID: 39419058; PMCID: PMC11602220.

20. Garcia-Basteiro AL, Ehrlich J, Bonnet M, Calnan M, Graham SM, Hermans S, Jarrett A, Lewa R, Mandalakas A, Martinez L, Migliori GB, Ong CWM, Otero L, Rangaka MX, Raviglione MCB, Seaworth B, Ssengooba W, Theron G, Trajman A, Behr MA. A Global Tuberculosis Dictionary: unified terms and definitions for the field of tuberculosis. Lancet Glob Health. 2024;12(5):e737-e9. doi: 10.1016/S2214-109X(24)00083-4. PubMed PMID: 38527468; PMCID: PMC11460053.

21. World Health Organization. WHO consolidated guidelines on tuberculosis: Module 6: Tuberculosis and comorbidities. . Geneva, Switzerland: 2024.

22. Atkinson A, Kraus D, Banholzer N, Miro JM, Reiss P, Kirk O, Mussini C, Morlat P, Podlekareva D, Grant AD, Sabin C, van der Valk M, Le Moing V, Meyer L, Seng R, Castagna A, Obel N, Antoniadou A, Salmon D, Zwahlen M, Egger M, de Wit S, Furrer H, Fenner L, Opportunistic Infections Project Working Group of the Collaboration of Observational HIVEREiE. HIV replication and tuberculosis risk among people living with HIV in Europe: A multicohort analysis, 1983-2015. PLoS One. 2024;19(10):e0312035. doi: 10.1371/journal.pone.0312035. PubMed PMID: 39453919; PMCID: PMC11508122.

23. Marquez C, Atukunda M, Nugent J, Charlebois ED, Chamie G, Mwangwa F, Ssemmondo E, Kironde J, Kabami J, Owaraganise A, Kakande E, Ssekaynzi B, Abbott R, Ayieko J, Ruel T, Kwariisima D, Kamya M, Petersen M, Havlir DV, Balzer LB. Community-Wide Universal HIV Test and Treat Intervention Reduces Tuberculosis Transmission in Rural Uganda: A Cluster-Randomized Trial. Clin Infect Dis. 2024;78(6):1601-7. doi: 10.1093/cid/ciad776. PubMed PMID: 38226445; PMCID: PMC11175690.

24. Ricks S, Denkinger CM, Schumacher SG, Hallett TB, Arinaminpathy N. The potential impact of urine-LAM diagnostics on tuberculosis incidence and mortality: A modelling analysis. PLoS Med. 2020;17(12):e1003466. doi: 10.1371/journal.pmed.1003466. PubMed PMID: 33306694; PMCID: PMC7732057.

25. Mangu C, Cossa M, Ndege R, Khosa C, Leukes V, de la Torre-Perez L, Machiana A, Kivuma B, Mnzava D, Zachariah C, Manjate P, Tagliani E, Schacht C, Buech J, Singh S, Ehrlich J, Riess F, Sanz S, Kranzer K, Cox H, Sabi I, Nguenha D, Meggi B, Weisser M, Ntinginya N, Schumacher S, Ruhwald M, Penn-Nicholson A, Garcia-Basteiro AL, Consortium T-C. Expanding Xpert MTB/RIF Ultra(R) and LF-LAM testing for diagnosis of tuberculosis among HIV-positive adults admitted to hospitals in Tanzania and Mozambique: a randomized controlled trial (the EXULTANT trial). BMC Infect Dis. 2024;24(1):831. doi: 10.1186/s12879-024-09651-z. PubMed PMID: 39148008; PMCID: PMC11325809.

26. Gerber F, Semphere R, Lukau B, Mahlatsi P, Mtenga T, Lee T, Kohler M, Glass TR, Amstutz A, Molatelle M, MacPherson P, Marake NB, Nliwasa M, Ayakaka I, Burke R, Labhardt N. Same-day versus rapid ART initiation in HIV-positive individuals presenting with symptoms of tuberculosis: Protocol for an open-label randomized non-inferiority trial in Lesotho and Malawi. PLoS One. 2024;19(2):e0288944. doi: 10.1371/journal.pone.0288944. PubMed PMID: 38330045; PMCID: PMC10852279.

27. Dong H, Feng J, Chang X, Wu S, Tang G, Liang F, Tang H, Dong Y, Fang W, Hu J, Wang W. Predictive value of systemic immune-inflammatory biomarkers for drug-induced liver injury in hepatitis B virus surface antigen positive tuberculosis patients: A retrospective observational study. Medicine (Baltimore). 2024;103(45):e40349. doi: 10.1097/MD.0000000000040349. PubMed PMID: 39533543; PMCID: PMC11556996.

28. Malden DE, Wong RJ, Chitnis AS, Im TM, Tartof SY. Screening Practices and Risk Factors for Co-Infection with Latent Tuberculosis and Hepatitis B Virus in an Integrated Healthcare System - California, 2008-2019. Am J Med. 2024;137(3):258-65 e3. doi: 10.1016/j.amjmed.2023.10.031. PubMed PMID: 38000687.

29. Wick JM, Ni Y, Halmer N, Wong RJ, Chitnis AS, Jaganath D, Krueger AL, Skarbinski J. Tuberculosis and Chronic Hepatitis B Virus Infection Screening Among Non-US-Born Persons in an Integrated Health System in California. Open Forum Infect Dis. 2024;11(9):ofae484. doi: 10.1093/ofid/ofae484. PubMed PMID: 39296340; PMCID: PMC11409871.

30. Favril L, Rich JD, Hard J, Fazel S. Mental and physical health morbidity among people in prisons: an umbrella review. Lancet Public Health. 2024;9(4):e250-e60. doi: 10.1016/S2468-2667(24)00023-9. PubMed PMID: 38553144.

31. Baauw A, Brouwers CFS, Afshar SF, van Goudoever JB, Chinapaw MJM, Hoogsteder MHH. Perspectives of refugee parents and unaccompanied minors on initial health assessment and access to care. Eur J Pediatr. 2024;183(7):2871-80. doi: 10.1007/s00431-024-05523-5. PubMed PMID: 38589580; PMCID: PMC11192806.

32. Murugan Y, Patel N, Kumar V, Gandhi R. Mental Health Impacts of Multidrug-Resistant Tuberculosis in Patients and Household Contacts: A Mixed Methods Study. Cureus. 2024;16(5):e60412. doi: 10.7759/cureus.60412. PubMed PMID: 38883116; PMCID: PMC11179742.

33. Dan-Ni Z, Guang-Min Z, Yu-Hua D, Ying L, Ting W, Yuan-Yuan C, Yu-Hong X, Xin-Cai X. Prevalence and risk factors of anxiety and depression in patients with multi-drug/rifampicin-resistant tuberculosis. Front Public Health. 2024;12:1372389. doi: 10.3389/fpubh.2024.1372389. PubMed PMID: 38601494; PMCID: PMC11004472.

34. Franco JV, Bongaerts B, Metzendorf MI, Risso A, Guo Y, Pena Silva L, Boeckmann M, Schlesinger S, Damen JA, Richter B, Baddeley A, Bastard M, Carlqvist A, Garcia-Casal MN, Hemmingsen B, Mavhunga F, Manne-Goehler J, Viney K. Diabetes as a risk factor for tuberculosis disease. Cochrane Database Syst Rev. 2024;8(8):CD016013. doi: 10.1002/14651858.CD016013.pub2. PubMed PMID: 39177079; PMCID: PMC11342417.

35. Kassie GA, Adella GA, Woldegeorgis BZ, Alemu A, Gebrekidan AY, Haile KE, Efa AG, Azeze GA, Asgedom YS. Burden of active tuberculosis among patients with diabetes mellitus in Sub-Saharan Africa: A systematic review and meta-analysis. Heliyon. 2024;10(21):e40140. doi: 10.1016/j.heliyon.2024.e40140. PubMed PMID: 39568839; PMCID: PMC11577225.

36. Zhao L, Gao F, Zheng C, Sun X. The Impact of Optimal Glycemic Control on Tuberculosis Treatment Outcomes in Patients With Diabetes Mellitus: Systematic Review and Meta-Analysis. JMIR Public Health Surveill. 2024;10:e53948. doi: 10.2196/53948. PubMed PMID: 38564244; PMCID: PMC11022131.

37. Kim JW, Bowman K, Nazareth J, Lee J, Woltmann G, Verma R, Sharifpour M, Shield C, Rees C, Kamil A, Swift B, Haldar P. PET-CT-guided characterisation of progressive, preclinical tuberculosis infection and its association with low-level circulating Mycobacterium tuberculosis DNA in household contacts in Leicester, UK: a prospective cohort study. Lancet Microbe. 2024;5(2):e119-e30. doi: 10.1016/S2666-5247(23)00289-6. PubMed PMID: 38244554.

38. Davies LRL, Wang C, Steigler P, Bowman KA, Fischinger S, Hatherill M, Fisher M, Mbandi SK, Rodo M, Ottenhoff THM, Dockrell HM, Sutherland JS, Mayanja-Kizza H, Boom WH, Walzl G, Kaufmann SHE, Nemes E, Scriba TJ, Lauffenburger D, Alter G, Fortune SM. Age and sex influence antibody profiles associated with tuberculosis progression. Nat Microbiol. 2024;9(6):1513-25. doi: 10.1038/s41564-024-01678-x. PubMed PMID: 38658786; PMCID: PMC11153143.

39. Martinez L, Seddon JA, Horsburgh CR, Lange C, Mandalakas AM, Consortium TBCS. Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing studies. Lancet Respir Med. 2024;12(8):633-41. doi: 10.1016/S2213-2600(24)00083-3. PubMed PMID: 38734022.

40. Ruslami R, Fregonese F, Apriani L, Barss L, Bedingfield N, Chiang V, Cook VJ, Fisher D, Flores E, Fox GJ, Johnston J, Lim RK, Long R, Paulsen C, Nguyen TA, Nhung NV, Gibson D, Valiquette C, Benedetti A, Menzies D. High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial. Lancet Respir Med. 2024;12(6):433-43. doi: 10.1016/S2213-2600(24)00076-6. PubMed PMID: 38552659.

41. Fox GJ, Nhung NV, Cam Binh N, Hoa NB, Garden FL, Benedetti A, Ngoc Yen P, Cuong NK, MacLean EL, Yapa HM, Dowdy DW, Lan NH, Guevara-Rattray E, Duc Cuong P, Solomon O, Behr MA, Marais BJ, Graham SM, Menzies D, Thu Anh N, Marks GB. Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis in Vietnam. N Engl J Med. 2024;391(24):2304-14. doi: 10.1056/NEJMoa2314325. PubMed PMID: 39693541.

42. Hesseling AC, Purchase SE, Martinson NA, Fairlie L, Schaaf HS, Brigden J, Staples S, Gibb DM, Garcia-Prats A, Conradie F, McGowan C, Layton C, Batist E, Demers AM, Nyamathe S, Frigati L, Turner R, Duong T, Seddon JA. Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis. N Engl J Med. 2024;391(24):2315-26. doi: 10.1056/NEJMoa2314318. PubMed PMID: 39693542.

43. Duong T, Brigden J, Simon Schaaf H, Garden F, Marais BJ, Anh Nguyen T, White IR, Gibb DM, Nhung NV, Martinson NA, Fairlie L, Martinez L, Layton C, Benedetti A, Marks GB, Turner RM, Seddon JA, Hesseling AC, Fox GJ. A Meta-Analysis of Levofloxacin for Contacts of Multidrug-Resistant Tuberculosis. NEJM Evid. 2025;4(1):EVIDoa2400190. doi: 10.1056/EVIDoa2400190. PubMed PMID: 39693627.

44. Zhou G, Luo S, He J, Chen N, Zhang Y, Cai S, Guo X, Chen H, Song C. Effectiveness and safety of tuberculosis preventive treatment for contacts of patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Clin Microbiol Infect. 2024;30(2):189-96. doi: 10.1016/j.cmi.2023.09.015. PubMed PMID: 37741621.

45. Duong T, Brigden J, Simon Schaaf H, Garden F, Marais BJ, Anh Nguyen T, White IR, Gibb DM, Nhung NV, Martinson NA, Fairlie L, Martinez L, Layton C, Benedetti A, Marks GB, Turner RM, Seddon JA, Hesseling AC, Fox GJ. A Meta-Analysis of Levofloxacin for Contacts of Multidrug-Resistant Tuberculosis. NEJM Evid. 2024:EVIDoa2400190. doi: 10.1056/EVIDoa2400190. PubMed PMID: 39693627.

46. Vasiliu A, Martinez L, Gupta RK, Hamada Y, Ness T, Kay A, Bonnet M, Sester M, Kaufmann SHE, Lange C, Mandalakas AM. Tuberculosis prevention: current strategies and future directions. Clin Microbiol Infect. 2024;30(9):1123-30. doi: 10.1016/j.cmi.2023.10.023. PubMed PMID: 37918510; PMCID: PMC11524220.

47. Dos Santos PCP, Messina NL, de Oliveira RD, da Silva PV, Puga MAM, Dalcolmo M, Dos Santos G, de Lacerda MVG, Jardim BA, de Almeida EVFF, Curtis N, Andrews JR, Croda J. Effect of BCG vaccination against Mycobacterium tuberculosis infection in adult Brazilian health-care workers: a nested clinical trial. Lancet Infect Dis. 2024;24(6):594-601. doi: 10.1016/S1473-3099(23)00818-6. PubMed PMID: 38423021; PMCID: PMC11111441.

48. Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Doherty RP, Marshall JL, Puig IC, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM, Team TBS. Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial. Lancet Infect Dis. 2024;24(3):285-96. doi: 10.1016/S1473-3099(23)00501-7. PubMed PMID: 38012890.

49. Pelzer PT, Stuck L, Martinez L, Richards AS, Acuna-Villaorduna C, Aronson NE, Bonnet M, Carvalho AC, Chan PC, Huang LM, Fang CT, Churchyard G, Corral-Londono HD, Datta M, Espinal MA, Fielding K, Fiore-Gartland AJ, Garcia-Basteiro A, Hanekom W, Hatherill M, Hill PC, Huerga H, Jones-Lopez EC, Kritski A, Mandalakas AM, Mangtani P, Martins Netto E, Mayanja H, Mazahir R, Murray M, Rangaka M, Scriba T, Singh J, Singh S, Stein CM, Vekemans J, Verhagen LM, Villalba JA, Wajja A, Watson B, White RG, Cobelens FGJ. Effectiveness of the primary Bacillus Calmette-Guerin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data. Lancet Microbe. 2024:100961. doi: 10.1016/j.lanmic.2024.100961. PubMed PMID: 39709975.

50. Satti I, Marshall JL, Harris SA, Wittenberg R, Tanner R, Lopez Ramon R, Wilkie M, Ramos Lopez F, Riste M, Wright D, Peralta Alvarez MP, Williams N, Morrison H, Stylianou E, Folegatti P, Jenkin D, Vermaak S, Rask L, Cabrera Puig I, Powell Doherty R, Lawrie A, Moss P, Hinks T, Bettinson H, McShane H. Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial. Lancet Infect Dis. 2024;24(8):909-21. doi: 10.1016/S1473-3099(24)00143-9. PubMed PMID: 38621405.

51. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection, third edition. Geneva: World Health Organization, 2024.

52. Saluzzo F, Masood F, Batignani V, Di Marco F, Majeed U, Ghazal A, Cirillo DM, Tahseen S. TB drug susceptibility testing in high fluoroquinolone resistance settings. IJTLD Open. 2024;1(5):230-5. doi: 10.5588/ijtldopen.24.0006. PubMed PMID: 39022777; PMCID: PMC11249602.

53. EUCAST Reference protocol for MIC determination of anti-tuberculous agents against isolates of the Mycobacterium tuberculosis complex in Middlebrook 7H9 broth Version 7.0. 2024.

54. Koser CU, Miotto P, Ismail N, Anthony RM, Utpatel C, Merker M, Niemann S, Tahseen S, Rigouts L, Rodrigues C, Omar SV, Farhat MR, Antonenka U, Hoffmann H, Cirillo DM, Schon T. A composite reference standard is needed for bedaquiline antimicrobial susceptibility testing for Mycobacterium tuberculosis complex. Eur Respir J. 2024;64(1). doi: 10.1183/13993003.00391-2024. PubMed PMID: 38991722; PMCID: PMC11237371.

55. Qin ZZ, Van der Walt M, Moyo S, Ismail F, Maribe P, Denkinger CM, Zaidi S, Barrett R, Mvusi L, Mkhondo N, Zuma K, Manda S, Koeppel L, Mthiyane T, Creswell J. Computer-aided detection of tuberculosis from chest radiographs in a tuberculosis prevalence survey in South Africa: external validation and modelled impacts of commercially available artificial intelligence software. Lancet Digit Health. 2024;6(9):e605-e13. doi: 10.1016/S2589-7500(24)00118-3. PubMed PMID: 39033067; PMCID: PMC11339183.

56. Stop TB Partnership. AI-Powered Cough Analysis and Monitoring 2024. Available from: https://www.stoptb.org/what-we-do/accelerate-tb-innovations/digital-health-technology-hub/ai-powered-cough-analysis-and-monitoring.

57. Kasule GW, Hermans S, Semugenze D, Wekiya E, Nsubuga J, Mwachan P, Kabugo J, Joloba M, Garcia-Basteiro AL, Ssengooba W, Stool TBGP. Non-sputum-based samples and biomarkers for detection of Mycobacterium tuberculosis: the hope to improve childhood and HIV-associated tuberculosis diagnosis. Eur J Med Res. 2024;29(1):502. doi: 10.1186/s40001-024-02092-z. PubMed PMID: 39420420; PMCID: PMC11487833.

58. Wood RC, Luabeya AK, Dragovich RB, Olson AM, Lochner KA, Weigel KM, Codsi R, Mulenga H, de Vos M, Kohli M, Penn-Nicholson A, Hatherill M, Cangelosi GA. Diagnostic accuracy of tongue swab testing on two automated tuberculosis diagnostic platforms, Cepheid Xpert MTB/RIF Ultra and Molbio Truenat MTB Ultima. J Clin Microbiol. 2024;62(4):e0001924. doi: 10.1128/jcm.00019-24. PubMed PMID: 38483169; PMCID: PMC11005402.

59. Steadman A, Andama A, Ball A, Mukwatamundu J, Khimani K, Mochizuki T, Asege L, Bukirwa A, Kato JB, Katumba D, Kisakye E, Mangeni W, Mwebe S, Nakaye M, Nassuna I, Nyawere J, Nakaweesa A, Cook C, Phillips P, Nalugwa T, Bachman CM, Semitala FC, Weigl BH, Connelly J, Worodria W, Cattamanchi A. New Manual Quantitative Polymerase Chain Reaction Assay Validated on Tongue Swabs Collected and Processed in Uganda Shows Sensitivity That Rivals Sputum-based Molecular Tuberculosis Diagnostics. Clin Infect Dis. 2024;78(5):1313-20. doi: 10.1093/cid/ciae041. PubMed PMID: 38306491; PMCID: PMC11093664.

60. Olson AM, Wood RC, Weigel KM, Yan AJ, Lochner KA, Dragovich RB, Luabeya AK, Yager P, Hatherill M, Cangelosi GA. High-sensitivity detection of Mycobacterium tuberculosis DNA in tongue swab samples. J Clin Microbiol. 2024:e0114024. doi: 10.1128/jcm.01140-24. PubMed PMID: 39745422.

61. Happaerts M, Lorent N, Andre E. Exploring the use of exhaled breath as a diagnostic tool for pulmonary TB. Int J Tuberc Lung Dis. 2024;28(7):317-21. doi: 10.5588/ijtld.23.0411. PubMed PMID: 38961554.

62. Pouzol S, Khaja Mafij Uddin M, Islam A, Jabin MS, Nigou J, Banu S, Hoffmann J. Combination of exhaled breath condensate samples with lipoarabinomannan point of care assay for pulmonary tuberculosis (TB) diagnosis: protocol for a diagnostic accuracy study. BMJ Open. 2024;14(9):e087026. doi: 10.1136/bmjopen-2024-087026. PubMed PMID: 39284696; PMCID: PMC11409364.

63. Bijker EM, Smith JP, McHembere W, McCarthy KD, Oord H, Gerritsen JW, Click ES, Cain K, Song R. Exhaled breath analysis: A promising triage test for tuberculosis in young children. Tuberculosis (Edinb). 2024;149:102566. doi: 10.1016/j.tube.2024.102566. PubMed PMID: 39332067.

64. Shaikh A, Sriraman K, Vaswani S, Shah I, Poojari V, Oswal V, Mane S, Rajagara S, Mistry N. SMaRT-PCR: sampling using masks and RT-PCR, a non-invasive diagnostic tool for paediatric pulmonary TB. Int J Tuberc Lung Dis. 2024;28(4):189-94. doi: 10.5588/ijtld.23.0291. PubMed PMID: 38563336.

65. Meiwes L, Kontsevaya I, Chesov D, Kulcitkaia S, Dreyer V, Hillemann D, Dlamini Q, Williams C, Barer M, Brinkmann F, Kruger R, Thee S, Kay A, Mandalakas AM, Lange C. Whispers in the wind: Face mask sampling for Mycobacterium tuberculosis detection in children with pulmonary tuberculosis. J Infect Dis. 2024. doi: 10.1093/infdis/jiae282. PubMed PMID: 38798080.

66. Mesman AW, Calderon RI, Hauns L, Pollock NR, Mendoza M, Holmberg RC, Franke MF. Detection of Mycobacterium tuberculosis transrenal DNA in urine samples among adults in Peru. Tuberculosis (Edinb). 2024;148:102549. doi: 10.1016/j.tube.2024.102549. PubMed PMID: 39098064; PMCID: PMC11381138.

67. Sossen B, Szekely R, Mukoka M, Muyoyeta M, Nakabugo E, Hella J, Van Nguyen H, Ubolyam S, Erkosar B, Vermeulen M, Centner CM, Nyangu S, Sanjase N, Sasamalo M, Dinh HT, Ngo TA, Manosuthi W, Jirajariyavej S, Nguyen NV, Avihingsanon A, Kerkhoff AD, Denkinger CM, Reither K, Nakiyingi L, MacPherson P, Meintjes G, Ruhwald M, Fuji LAMSC. Urine-Xpert Ultra for the diagnosis of tuberculosis in people living with HIV: a prospective, multicentre, diagnostic accuracy study. Lancet Glob Health. 2024;12(12):e2024-34. doi: 10.1016/S2214-109X(24)00357-7. PubMed PMID: 39577975; PMCID: PMC11584317.

68. Szekely R, Sossen B, Mukoka M, Muyoyeta M, Nakabugo E, Hella J, Nguyen HV, Ubolyam S, Chikamatsu K, Mace A, Vermeulen M, Centner CM, Nyangu S, Sanjase N, Sasamalo M, Dinh HT, Ngo TA, Manosuthi W, Jirajariyavej S, Mitarai S, Nguyen NV, Avihingsanon A, Reither K, Nakiyingi L, Kerkhoff AD, MacPherson P, Meintjes G, Denkinger CM, Ruhwald M, Fuji LAMSC. Prospective multicentre accuracy evaluation of the FUJIFILM SILVAMP TB LAM test for the diagnosis of tuberculosis in people living with HIV demonstrates lot-to-lot variability. PLoS One. 2024;19(5):e0303846. doi: 10.1371/journal.pone.0303846. PubMed PMID: 38820372; PMCID: PMC11142480.

69. Hoa NB, Fajans M, Nguyen Van H, Vu Ngoc B, Nguyen Viet N, Nguyen Thi H, Thi Huong LT, Tran Minh D, Nguyen Kim C, Thi Tuyet TH, Huu TN, Bui Ngoc D, Nguyen Viet H, Khanh AT, Lillis L, Perez M, Thomas KK, Peck RB, Cantera JL, Murphy E, Halas OR, Storey HL, Pinter A, Ruhwald M, Drain PK, Boyle DS. Urine lipoarabinomannan concentrations among HIV-negative adults with pulmonary or extrapulmonary tuberculosis disease in Vietnam. PLOS Glob Public Health. 2024;4(11):e0003891. doi: 10.1371/journal.pgph.0003891. PubMed PMID: 39504319; PMCID: PMC11540228.

70. Carratala-Castro L, Ssengooba W, Kay A, Acacio S, Ehrlich J, DiNardo AR, Shiba N, Nsubuga JK, Munguambe S, Saavedra-Cervera B, Manjate P, Mulengwa D, Sibandze B, Ziyane M, Kasule G, Mambuque E, Sekadde MP, Wobudeya E, Joloba ML, Heyckendorf J, Lange C, Hermans S, Mandalakas A, Garcia-Basteiro AL, Lopez-Varela E, Stool TBGP. A stool based qPCR for the diagnosis of TB in children and people living with HIV in Uganda, Eswatini and Mozambique (Stool4TB): a protocol for a multicenter diagnostic evaluation. BMC Infect Dis. 2024;24(1):233. doi: 10.1186/s12879-023-08708-9. PubMed PMID: 38383310; PMCID: PMC10880221.

71. Macaux L, Rasolofo V, Eyangoh S, N’Guessan KR, Tejiokem MC, Rakotosamimanana N, Soumahoro MK, Cauchemez S, Randremanana RV, group T-Ks. Accuracy of Xpert and alternative sampling methods to diagnose childhood pulmonary tuberculosis, a prospective cohort study. Clin Microbiol Infect. 2024. doi: 10.1016/j.cmi.2024.11.002. PubMed PMID: 39522607.

72. Moreto-Planas L, Mahajan R, Fidelle Nyikayo L, Ajack YBP, Tut Chol B, Osman E, Sangma M, Tobi A, Gallo J, Biague E, Goncalves R, Rocaspana M, Medina C, Camara M, Flevaud L, Ruby LC, Belard S, Sagrado MJ, Molina I, Llosa AE. Xpert-Ultra Assay in Stool and Urine Samples to Improve Tuberculosis Diagnosis in Children: The Medecins Sans Frontieres Experience in Guinea-Bissau and South Sudan. Open Forum Infect Dis. 2024;11(5):ofae221. doi: 10.1093/ofid/ofae221. PubMed PMID: 38798893; PMCID: PMC11119760.

73. Kay A, Vasiliu A, Carratala-Castro L, Mtafya B, Mendez Reyes JE, Maphalala N, Munguambe S, Mulengwa D, Ness T, Saavedra B, Bacha J, Maphalala G, Mejia R, Mtetwa G, Acacio S, Manjate P, Mambuque E, Shiba N, Kota N, Ziyane M, Ntinginya NE, Lange C, Kirchner HL, DiNardo AR, Garcia-Basteiro AL, Mandalakas AM, Stool TBGP. Performance of a stool-based quantitative PCR assay for the diagnosis of tuberculosis in adolescents and adults: a multinational, prospective diagnostic accuracy study. Lancet Microbe. 2024;5(5):e433-e41. doi: 10.1016/S2666-5247(23)00391-9. PubMed PMID: 38461830; PMCID: PMC11142891.

74. Akinaga A, Takahashi M, Yamazaki T, Chikamatsu K, Matsushita S, Hashimoto Y, Iyoda T, Saika T, Mitarai S. Development and preliminary evaluation toward a new tuberculosis treatment monitoring tool: the PATHFAST TB LAM Ag assay. J Clin Microbiol. 2024;62(8):e0062924. doi: 10.1128/jcm.00629-24. PubMed PMID: 39028178; PMCID: PMC11323533.

75. Musisi E, Wamutu S, Ssengooba W, Kasiinga S, Sessolo A, Sanyu I, Kaswabuli S, Zawedde J, Byanyima P, Kia P, Muwambi W, Toskin DT, Kigozi E, Walbaum N, Dombay E, Legrady MB, Ssemambo KD, Joloba M, Kuchaka D, Worodria W, Huang L, Gillespie SH, Sabiiti W. Accuracy of the tuberculosis molecular bacterial load assay to diagnose and monitor response to anti-tuberculosis therapy: a longitudinal comparative study with standard-of-care smear microscopy, Xpert MTB/RIF Ultra, and culture in Uganda. Lancet Microbe. 2024;5(4):e345-e54. doi: 10.1016/S2666-5247(23)00367-1. PubMed PMID: 38458206.

76. Neumann M, Reimann M, Chesov D, Popa C, Dragomir A, Popescu O, Munteanu R, Holscher A, Honeyborne I, Heyckendorf J, Lange C, Holscher C, Kalsdorf B. The Molecular Bacterial Load Assay predicts treatment responses in patients with pre-XDR/XDR-tuberculosis more accurately than GeneXpert Ultra MTB/Rif. J Infect. 2024:106399. doi: 10.1016/j.jinf.2024.106399. PubMed PMID: 39733827.

77. Kutame R, Boateng G, Adusi-Poku Y, Sorvor F, Antwi L, Agyemang-Bioh F, Ayensu B, Gyau-Boateng V, Asiedu-Bekoe F. Evaluation of Diagnostic Performance of Three Commercial Interferon-Gamma Release Assays for Mycobacterium tuberculosis. Diagnostics (Basel). 2024;14(19). doi: 10.3390/diagnostics14192130. PubMed PMID: 39410534; PMCID: PMC11475782.

78. Liu Y, Fang M, Yuan C, Yang Y, Yu L, Li Y, Hu L, Li J. Combining interferon-gamma release assays and metagenomic next-generation sequencing for diagnosis of pulmonary tuberculosis: a retrospective study. BMC Infect Dis. 2024;24(1):1316. doi: 10.1186/s12879-024-10206-5. PubMed PMID: 39558256; PMCID: PMC11575000.

79. Nakiboneka R, Walbaum N, Musisi E, Nevels M, Nyirenda T, Nliwasa M, Msefula CL, Sloan D, Sabiiti W. Specific human gene expression in response to infection is an effective marker for diagnosis of latent and active tuberculosis. Sci Rep. 2024;14(1):26884. doi: 10.1038/s41598-024-77164-5. PubMed PMID: 39505948; PMCID: PMC11541504.

80. Liu YH, Su JW, Jiang J, Yang BF, Cao ZH, Zhai F, Sun WN, Zhang LX, Cheng XX. Development of a Nomogram Based on Transcriptional Signatures, IFN-gamma Response and Neutrophils for Diagnosis of Tuberculosis. J Inflamm Res. 2024;17:8799-811. doi: 10.2147/JIR.S480173. PubMed PMID: 39559398; PMCID: PMC11570532.

81. Ji Z, Bi S, Lu B, Zheng L, Jin X, Huang S, Jiang L, Wang Y, Ding C, Xu K. Diagnostic Efficiency of the Blood-Based Cepheid 3-Gene Host Response Test and Urine-Based Lipoarabinomannan for Active Tuberculosis Case Detection at a General Hospital in China. Infect Drug Resist. 2024;17:4467-75. doi: 10.2147/IDR.S484123. PubMed PMID: 39435459; PMCID: PMC11492898.

82. Vito O, Psarras S, Syggelou A, Wright VJ, Amanatidou V, Newton SM, Shailes H, Trochoutsou K, Tsagaraki M, Levin M, Kaforou M, Tsolia M. Novel RNA biomarkers improve discrimination of children with tuberculosis disease from those with non-TB pneumonia after in vitro stimulation. Front Immunol. 2024;15:1401647. doi: 10.3389/fimmu.2024.1401647. PubMed PMID: 39391304; PMCID: PMC11464340.

83. Lai H, Lyu M, Ruan H, Liu Y, Liu T, Lei S, Xiao Y, Zhang S, Ying B. Large-scale analysis reveals splicing biomarkers for tuberculosis progression and prognosis. Comput Biol Med. 2024;171:108187. doi: 10.1016/j.compbiomed.2024.108187. PubMed PMID: 38402840.

84. Mendelsohn SC, Andrade BB, Mbandi SK, Andrade AMS, Muwanga VM, Figueiredo MC, Erasmus M, Rolla VC, Thami PK, Cordeiro-Santos M, Penn-Nicholson A, Kritski AL, Hatherill M, Sterling TR, Scriba TJ, Re P-SA, Re P-BC. Transcriptomic signatures of progression to TB disease among close contacts in Brazil. J Infect Dis. 2024. doi: 10.1093/infdis/jiae237. PubMed PMID: 38709708.

85. Nii Otinkorang Ankrah J, Gyilbagr F, Vicar EK, Antwi Boasiako Frimpong E, Alhassan RB, Sibdow Baako I, Boakye AN, Akwetey SA, Karikari AB, Sorvor FKB, Walana W. T cells exhaustion, inflammatory and cellular activity markers in PBMCs predict treatment outcome in pulmonary tuberculosis patients. Cytokine. 2024;182:156708. doi: 10.1016/j.cyto.2024.156708. PubMed PMID: 39053080.

86. Chang A, Loy CJ, Eweis-LaBolle D, Lenz JS, Steadman A, Andgrama A, Nhung NV, Yu C, Worodria W, Denkinger CM, Nahid P, Cattamanchi A, De Vlaminck I. Circulating cell-free RNA in blood as a host response biomarker for detection of tuberculosis. Nat Commun. 2024;15(1):4949. doi: 10.1038/s41467-024-49245-6. PubMed PMID: 38858368; PMCID: PMC11164910.

87. Li G, Cannon K, Sisniega C, Fergie J. Cell-free DNA blood test for the diagnosis of pediatric tuberculous meningitis. J Clin Tuberc Other Mycobact Dis. 2024;35:100421. doi: 10.1016/j.jctube.2024.100421. PubMed PMID: 38420617; PMCID: PMC10899014.

88. Branigan D. TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing. Treatment Action Group, 2024.

89. Cevik M, Thompson LC, Upton C, Rolla VC, Malahleha M, Mmbaga B, Ngubane N, Abu Bakar Z, Rassool M, Variava E, Dawson R, Staples S, Lalloo U, Louw C, Conradie F, Eristavi M, Samoilova A, Skornyakov SN, Ntinginya NE, Haraka F, Praygod G, Mayanja-Kizza H, Caoili J, Balanag V, Dalcolmo MP, McHugh T, Hunt R, Solanki P, Bateson A, Crook AM, Fabiane S, Timm J, Sun E, Spigelman M, Sloan DJ, Gillespie SH, Simplici TBC. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024;24(9):1003-14. doi: 10.1016/S1473-3099(24)00223-8. PubMed PMID: 38768617.

90. Burman W, Horsburgh CR, Johnston J. Predictable excess hepatotoxicity in the SimpliciTB trial. Lancet Infect Dis. 2024;24(12):e727. doi: 10.1016/S1473-3099(24)00598-X. PubMed PMID: 39481423.

91. Dooley KE, Hendricks B, Gupte N, Barnes G, Narunsky K, Whitelaw C, Smit T, Ignatius EH, Friedman A, Dorman SE, Dawson R, Assessing Pretomanid for Tuberculosis Study T. Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results. Am J Respir Crit Care Med. 2023;207(7):929-35. doi: 10.1164/rccm.202208-1475OC. PubMed PMID: 36455068.

92. Tweed CD, Wills GH, Crook AM, Amukoye E, Balanag V, Ban AYL, Bateson ALC, Betteridge MC, Brumskine W, Caoili J, Chaisson RE, Cevik M, Conradie F, Dawson R, Del Parigi A, Diacon A, Everitt DE, Fabiane SM, Hunt R, Ismail AI, Lalloo U, Lombard L, Louw C, Malahleha M, McHugh TD, Mendel CM, Mhimbira F, Moodliar RN, Nduba V, Nunn AJ, Sabi I, Sebe MA, Selepe RAP, Staples S, Swindells S, van Niekerk CH, Variava E, Spigelman M, Gillespie SH. A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB. Int J Tuberc Lung Dis. 2021;25(4):305-14. doi: 10.5588/ijtld.20.0513. PubMed PMID: 33762075; PMCID: PMC8009598.

93. Chang VK, Imperial MZ, Phillips PPJ, Velasquez GE, Nahid P, Vernon A, Kurbatova EV, Swindells S, Chaisson RE, Dorman SE, Johnson JL, Weiner M, Sizemore EE, Whitworth W, Carr W, Bryant KE, Burton D, Dooley KE, Engle M, Nsubuga P, Diacon AH, Nhung NV, Dawson R, Savic RM, Group ACT, Tuberculosis Trials C. Risk-stratified treatment for drug-susceptible pulmonary tuberculosis. Nat Commun. 2024;15(1):9400. doi: 10.1038/s41467-024-53273-7. PubMed PMID: 39477924; PMCID: PMC11526018.

94. Diacon AH, Barry CE, 3rd, Carlton A, Chen RY, Davies M, de Jager V, Fletcher K, Koh G, Kontsevaya I, Heyckendorf J, Lange C, Reimann M, Penman SL, Scott R, Maher-Edwards G, Tiberi S, Vlasakakis G, Upton CM, Aguirre DB. A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nat Med. 2024;30(3):896-904. doi: 10.1038/s41591-024-02829-7. PubMed PMID: 38365949; PMCID: PMC10957473.

95. Lienhardt C, Dooley KE, Nahid P, Wells C, Ryckman TS, Kendall EA, Davies G, Brigden G, Churchyard G, Cirillo DM, Di Meco E, Gopinath R, Mitnick C, Scott C, Amanullah F, Bansbach C, Boeree M, Campbell M, Conradie F, Crook A, Daley CL, Dheda K, Diacon A, Gebhard A, Hanna D, Heinrich N, Hesseling A, Holtzman D, Jachym M, Kim P, Lange C, McKenna L, Meintjes G, Ndjeka N, Nhung NV, Nyang’wa BT, Paton NI, Rao R, Rich M, Savic R, Schoeman I, Makokotlela BS, Spigelman M, Sun E, Svensson E, Tisile P, Varaine F, Vernon A, Diul MY, Kasaeva T, Zignol M, Gegia M, Mirzayev F, Schumacher SG. Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024;102(8):600-7. doi: 10.2471/BLT.24.291881. PubMed PMID: 39070602; PMCID: PMC11276158.

96. Ryckman TS, Schumacher SG, Lienhardt C, Sweeney S, Dowdy DW, Mirzayev F, Kendall EA. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis. Lancet Glob Health. 2024;12(6):e995-e1004. doi: 10.1016/S2214-109X(24)00088-3. PubMed PMID: 38762299; PMCID: PMC11126367.

97. Nsengiyumva NP, Khan A, Gler M, Tonquin ML, Marcelo D, Andrews MC, Duverger K, Ahmed S, Ibrahim T, Banu S, Sultana S, Morales ML, Villanueva A, Efo E, Onjare B, Celan C, Schwartzman K. Costs of Digital Adherence Technologies for Tuberculosis Treatment Support, 2018-2021. Emerg Infect Dis. 2024;30(1):79-88. doi: 10.3201/eid3001.230427. PubMed PMID: 38146969; PMCID: PMC10756355.

98. Dheda K, Mirzayev F, Cirillo DM, Udwadia Z, Dooley KE, Chang KC, Omar SV, Reuter A, Perumal T, Horsburgh CR, Jr., Murray M, Lange C. Multidrug-resistant tuberculosis. Nat Rev Dis Primers. 2024;10(1):22. doi: 10.1038/s41572-024-00504-2. PubMed PMID: 38523140.

99. Motta I, Boeree M, Chesov D, Dheda K, Gunther G, Horsburgh CR, Jr., Kherabi Y, Lange C, Lienhardt C, McIlleron HM, Paton NI, Stagg HR, Thwaites G, Udwadia Z, Van Crevel R, Velasquez GE, Wilkinson RJ, Guglielmetti L, Study group on Mycobacteria of the European Society of Clinical M, Infectious D. Recent advances in the treatment of tuberculosis. Clin Microbiol Infect. 2024;30(9):1107-14. doi: 10.1016/j.cmi.2023.07.013. PubMed PMID: 37482332.

100. Hoelscher M, Barros-Aguirre D, Dara M, Heinrich N, Sun E, Lange C, Tiberi S, Wells C. Candidate anti-tuberculosis medicines and regimens under clinical evaluation. Clin Microbiol Infect. 2024;30(9):1131-8. doi: 10.1016/j.cmi.2024.06.016. PubMed PMID: 38909687.

101. Nyang’wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Moodliar R, Dodd M, Solodovnikova V, Liverko I, Rajaram S, Rassool M, McHugh T, Spigelman M, Moore DA, Ritmeijer K, du Cros P, Fielding K, team T-P. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med. 2024;12(2):117-28. doi: 10.1016/S2213-2600(23)00389-2. PubMed PMID: 37980911.

102. Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M, Soe M, Abdrasuliev T, Usmanova R, Butabekov I, Nikolaevna TZ, Liverko I, Parpieva N, Moodliar R, Solodovnikova V, Kazounis E, Nyang’wa BT, Fielding KL, Berry C. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial. Antimicrob Agents Chemother. 2024;68(7):e0053624. doi: 10.1128/aac.00536-24. PubMed PMID: 38842323; PMCID: PMC11232376.

103. Padmapriyadarsini C, Oswal VS, Jain CD, Mariappan MV, Singla N, Kumar S, Daniel BD, Dave JD, Vadgama P, Ramraj B, Kant S, Bhatnagar AK, Shanmugam S, Paul D, Bharathi J, Palav M, Shah NV, Santhanakrishnan R, Dewan RK, Shekh N, Rathinam P, Sisara AB, Mankar SD, Bajpai J, Mittal U, Chauhan S, Kumar R, Parmar M, Mattoo SK, Jaju J, modified BST. Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial. Clin Infect Dis. 2024. doi: 10.1093/cid/ciae388. PubMed PMID: 39194339.

104. Gunther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C, Tuberculosis Network European Trials g. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe. Clin Microbiol Infect. 2024;30(9):1197 e1- e4. doi: 10.1016/j.cmi.2024.03.009. PubMed PMID: 38490355.

105. Korotych O, Achar J, Gurbanova E, Hovhannesyan A, Lomtadze N, Ciobanu A, Skrahina A, Dravniece G, Kuksa L, Rich M, Khachatryan N, Germanovych M, Kadyrov A, Terleieva I, Akhundova I, Adenov M, Durdyeva M, Kiria N, Parpieva N, Yatskevich N, Jumayev R, Nurov R, Diktanas S, Vilc V, Migliori GB, Yedilbayev A. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study. Lancet Infect Dis. 2024;24(10):1151-61. doi: 10.1016/S1473-3099(24)00228-7. PubMed PMID: 38880112; PMCID: PMC11424498.

106. Rashitov M, Franke MF, Trevisi L, Bekbolatova G, Shalimova J, Eshmetov G, Bektasov S, LaHood A, Arlyapova N, Osso E, Yedilbayev A, Korotych O, Ciobanu A, Skrahina A, Mitnick CD, Seung KJ, Algozhin Y, Rich ML. Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan. Clin Infect Dis. 2024;79(4):1046-53. doi: 10.1093/cid/ciae305. PubMed PMID: 38833593; PMCID: PMC11478590.

107. Mesic A, Decuyper I, Ishaq S, Azizi T, Ziamal FH, Amiri S, Keus K, Thandar Pyae M, Mangal KM, Amirzada HK, Rasooli A, Aloudal MR, Daldar MZ, Decroo T. Short oral treatment regimens for rifampicin-resistant tuberculosis are safe and effective for young children: results from a field-based, non-randomised clinical trial from Kandahar, Afghanistan. Eur Respir J. 2024;63(5). doi: 10.1183/13993003.00436-2024. PubMed PMID: 38782466; PMCID: PMC11137330.

108. Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A, Baudin E, Berikova E, Berry C, Bonnet M, Cellamare M, Chavan V, Cox V, Dakenova Z, de Jong BC, Ferlazzo G, Karabayev A, Kirakosyan O, Kiria N, Kunda M, Lachenal N, Lecca L, McIlleron H, Motta I, Toscano SM, Mushtaque H, Nahid P, Oyewusi L, Panda S, Patil S, Phillips PPJ, Ruiz J, Salahuddin N, Garavito ES, Seung KJ, Ticona E, Trippa L, Vasquez DEV, Wasserman S, Rich ML, Varaine F, Mitnick CD, end TBCTT. Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis. N Engl J Med. 2025;392(5):468-82. doi: 10.1056/NEJMoa2400327. PubMed PMID: 39879593; PMCID: PMC7617355.

109. World Health Organization. Key updates to the treatment of drug-resistant tuberculosis: rapid communication. Geneva, Switzerland: 2024.

110. Kho S, Seung KJ, Huerga H, Bastard M, Khan PY, Mitnick CD, Rich ML, Islam S, Zhizhilashvili D, Yeghiazaryan L, Nikolenko EN, Zarli K, Adnan S, Salahuddin N, Ahmed S, Vargas ZHR, Bekele A, Shaimerdenova A, Tamirat M, Gelin A, Vilbrun SC, Hewison C, Khan U, Franke M. Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis. Nat Commun. 2024;15(1):3927. doi: 10.1038/s41467-024-48077-8. PubMed PMID: 38724531; PMCID: PMC11082252.

111. Campbell JR, Brode SK, Barry P, Bastos ML, Bonnet M, Guglielmetti L, Kempker R, Klimuk D, Laniado Laborin R, Milanov V, Singla R, Skrahina A, Trajman A, van der Werf TS, Viiklepp P, Menzies D. Association of indicators of extensive disease and rifampin-resistant tuberculosis treatment outcomes: an individual participant data meta-analysis. Thorax. 2024;79(2):169-78. doi: 10.1136/thorax-2023-220249. PubMed PMID: 38135489.

112. Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2018;24(11):1708-15. doi: 10.1038/s41591-018-0224-2. PubMed PMID: 30397355; PMCID: PMC6685538.

113. Gausi K, Ignatius EH, De Jager V, Upton C, Kim S, McKhann A, Moran L, Wiesner L, von Groote-Bidlingmaier F, Marzinek P, Vanker N, Yvetot J, Pierre S, Rosenkranz SL, Swindells S, Diacon AH, Nuermberger EL, Denti P, Dooley KE. High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial. Am J Respir Crit Care Med. 2024;210(3):343-51. doi: 10.1164/rccm.202311-2004OC. PubMed PMID: 38564365; PMCID: PMC11348975.

114. Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, Ignatius EH, Nuermberger EL, Moran L, Donahue K, Swindells S, Vanker N, Diacon AH, Team AS. Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial. Am J Respir Crit Care Med. 2020;201(11):1416-24. doi: 10.1164/rccm.201910-1960OC. PubMed PMID: 31945300; PMCID: PMC7258626.

115. The BETTER Project. Best Practices for Clinical Management of Tuberculosis with Expanded Resistance: A Field Guide. . Cleveland, OH, USA: 2024.

116. Payne P, Hayward SE, Pareek M, Smyth A, Kerr L, Clemente NS, Hargreaves S, Nellums LB. Distribution of tuberculosis in migrant children and young people in Europe: a retrospective database analysis of European data. Public Health. 2024;233:100-7. doi: 10.1016/j.puhe.2024.04.001. PubMed PMID: 38865826.

117. da Costa FBP, Nicol MP, Botha M, Workman L, Arcencio RA, Zar HJ, Martinez L. Mycobacterium tuberculosis infection and tuberculosis disease in the first decade of life: a South African birth cohort study. Lancet Child Adolesc Health. 2024;8(12):891-9. doi: 10.1016/S2352-4642(24)00256-6. PubMed PMID: 39515364; PMCID: PMC11579303.

118. Rodriguez-Molino P, Tebruegge M, Noguera-Julian A, Neth O, Fidler K, Brinkmann F, Sainz T, Ivaskeviciene I, Ritz N, Brito MJ, Milheiro Silva T, Chechenieva V, Serdiuk M, Lancella L, Russo C, Soler-Garcia A, Navarro ML, Krueger R, Feiterna-Sperling C, Starshinova A, Hiteva A, Hoffmann A, Kalibatas P, Lo Vecchio A, Scarano SM, Bustillo M, Blazquez Gamero D, Espiau M, Buonsenso D, Falcon L, Turnbull L, Colino E, Rueda S, Buxbaum C, Carazo B, Alvarez C, Dapena M, Piqueras A, Velizarova S, Ozere I, Gotzinger F, Pareja M, Garrote Llanos MI, Soto B, Rodriguez Martin S, Korta JJ, Perez-Gorricho B, Herranz M, Hernandez-Bartolome A, Diaz-Almiron M, Kohns Vasconcelos M, Ferreras-Antolin L, Santiago-Garcia B. Tuberculosis Disease in Immunocompromised Children and Adolescents: A Pediatric Tuberculosis Network European Trials Group Multicenter Case-control Study. Clin Infect Dis. 2024;79(1):215-22. doi: 10.1093/cid/ciae158. PubMed PMID: 38568992.

119. Williams CM, Muhammad AK, Sambou B, Bojang A, Jobe A, Daffeh GK, Owolabi O, Pan D, Pareek M, Barer MR, Sutherland JS, Haldar P. Exhaled Mycobacterium tuberculosis Predicts Incident Infection in Household Contacts. Clin Infect Dis. 2023;76(3):e957-e64. doi: 10.1093/cid/ciac455. PubMed PMID: 36350995; PMCID: PMC9907542.

120. Olbrich L, Verghese VP, Franckling-Smith Z, Sabi I, Ntinginya NE, Mfinanga A, Banze D, Viegas S, Khosa C, Semphere R, Nliwasa M, McHugh TD, Larsson L, Razid A, Song R, Corbett EL, Nabeta P, Trollip A, Graham SM, Hoelscher M, Geldmacher C, Zar HJ, Michael JS, Heinrich N, RaPaed TBc. Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries. Lancet Infect Dis. 2024;24(2):140-9. doi: 10.1016/S1473-3099(23)00491-7. PubMed PMID: 37918414; PMCID: PMC10808504.

121. Nkereuwem E, Agbla S, Njai B, Edem VF, Jatta ML, Owolabi O, Masterton U, Jah F, Danso M, Fofana AN, Samateh W, Darboe ML, Owusu SA, Bush A, Kampmann B, Togun T. Post-tuberculosis respiratory impairment in Gambian children and adolescents: A cross-sectional analysis. Pediatr Pulmonol. 2024;59(7):1912-21. doi: 10.1002/ppul.27009. PubMed PMID: 38629432.

122. van der Zalm MM, Jongen VW, Swanepoel R, Zimri K, Allwood B, Palmer M, Dunbar R, Goussard P, Schaaf HS, Hesseling AC, Seddon JA. Impaired lung function in adolescents with pulmonary tuberculosis during treatment and following treatment completion. EClinicalMedicine. 2024;67:102406. doi: 10.1016/j.eclinm.2023.102406. PubMed PMID: 38261903; PMCID: PMC10796966.

123. Gray DM, Githinji L, Brittain K, Franckling-Smith Z, Bateman L, Prins M, Baard CB, McFarlane D, Nicol MP, Workman L, Zar HJ. Lung function trajectories in South African children with pulmonary tuberculosis compared to those with non-TB lower respiratory tract infection: a prospective study. Eur Respir J. 2024;63(5). doi: 10.1183/13993003.00216-2024. PubMed PMID: 38782467.

124. Hermansen TS, Ravn P, Svensson E, Lillebaek T. Nontuberculous mycobacteria in Denmark, incidence and clinical importance during the last quarter-century. Sci Rep. 2017;7(1):6696. doi: 10.1038/s41598-017-06931-4. PubMed PMID: 28751677; PMCID: PMC5532240.

125. Andrejak C, Thomsen VO, Johansen IS, Riis A, Benfield TL, Duhaut P, Sorensen HT, Lescure FX, Thomsen RW. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med. 2010;181(5):514-21. doi: 10.1164/rccm.200905-0778OC. PubMed PMID: 20007929.

126. Wetzstein N, Dahl VN, Lillebaek T, Lange C. Clinical spectrum and relevance of Mycobacterium malmoense: Systematic review and meta-analysis of 859 patients. J Infect. 2024;89(2):106203. doi: 10.1016/j.jinf.2024.106203. PubMed PMID: 38906266.

127. Lange C, Bottger EC, Cambau E, Griffith DE, Guglielmetti L, van Ingen J, Knight SL, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, Wagner D, Winthrop K, Daley CL, expert panel group for management recommendations in non-tuberculous mycobacterial pulmonary d. Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infect Dis. 2022;22(7):e178-e90. doi: 10.1016/S1473-3099(21)00586-7. PubMed PMID: 35090639.

128. Loebinger MR, Aliberti S, Haworth C, Jankovic Makek M, Lange C, Lorent N, Papavasileiou A, Polverino E, Rohde G, Veziris N, Wagner D, van Ingen J. Patients at risk of nontuberculous mycobacterial pulmonary disease who need testing evaluated using a modified Delphi process by European experts. ERJ Open Res. 2024;10(5). doi: 10.1183/23120541.00791-2023. PubMed PMID: 39319044; PMCID: PMC11417603.

129. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Jr., Andrejak C, Bottger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56(1). doi: 10.1183/13993003.00535-2020. PubMed PMID: 32636299; PMCID: PMC8375621.

130. Choi H, Hughes C, Eke Z, Shuttleworth M, Shteinberg M, Polverino E, Goeminne PC, Welte T, Blasi F, Shoemark A, Long MB, Aliberti S, Haworth CS, Ringshausen FC, Loebinger MR, Lorent N, Chalmers JD. Clinical Efficacy of Serum Antiglycopeptidolipid Core IgA Antibody Test for Screening Nontuberculous Mycobacterial Pulmonary Disease in Bronchiectasis: A European Multicenter Cohort Study. Chest. 2024. doi: 10.1016/j.chest.2024.10.029. PubMed PMID: 39490969.

131. Kitada S, Yoshimura K, Miki K, Miki M, Hashimoto H, Matsui H, Kuroyama M, Ageshio F, Kagawa H, Mori M, Maekura R, Kobayashi K. Validation of a commercial serodiagnostic kit for diagnosing pulmonary Mycobacterium avium complex disease. Int J Tuberc Lung Dis. 2015;19(1):97-103. doi: 10.5588/ijtld.14.0564. PubMed PMID: 25519798.

132. Li L, Henkle E, Youngquist BM, Seo S, Hamed K, Melnick D, Lyon CJ, Jiang L, Zelazny AM, Hu TY, Winthrop KL, Ning B. Serum Cell-Free DNA-based Detection of Mycobacterium avium Complex Infection. Am J Respir Crit Care Med. 2024;209(10):1246-54. doi: 10.1164/rccm.202303-0401OC. PubMed PMID: 38190702; PMCID: PMC11146540.

133. van Ingen J, Hoefsloot W, Dartois V, Dick T. Rifampicin has no role in treatment of Mycobacterium avium complex pulmonary disease and bactericidal sterilising drugs are needed: a viewpoint. Eur Respir J. 2024;63(5). doi: 10.1183/13993003.02210-2023. PubMed PMID: 38697635; PMCID: PMC11063616.

134. Stemkens R, Lemson A, Koele SE, Svensson EM, Te Brake LHM, van Crevel R, Boeree MJ, Hoefsloot W, van Ingen J, Aarnoutse RE. A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease. J Antimicrob Chemother. 2024;79(12):3100-8. doi: 10.1093/jac/dkae309. PubMed PMID: 39378281; PMCID: PMC11638672.

135. Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O’Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ, Jr., van Ingen J, Coulter C, Nezamis J, Winthrop KL, Group CS. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018;198(12):1559-69. doi: 10.1164/rccm.201807-1318OC. PubMed PMID: 30216086.

136. Daley CL, Chalmers JD, Flume PA, Griffith DE, Hasegawa N, Morimoto K, Winthrop KL, Sheu CC, Hassan M, Nevoret ML, Ciesielska M, Yuen DW, Mange KC. Microbiologic Outcomes From a Randomized, Double-blind Trial of Amikacin Liposome Inhalation Suspension in Adults With Newly Diagnosed or Recurrent Mycobacterium Avium Complex Lung Disease: The ARISE Study (abstract). Am J Respir Crit Care Med 2024;209:A1033.

137. Dartois V, Dick T. Toward better cures for Mycobacterium abscessus lung disease. Clin Microbiol Rev. 2024;37(4):e0008023. doi: 10.1128/cmr.00080-23. PubMed PMID: 39360834; PMCID: PMC11629636.

138. Nguyen MH, Haas MK, Kasperbauer SH, Calado Nogueira de Moura V, Eddy JJ, Mitchell JD, Khare R, Griffith DE, Chan ED, Daley CL. Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects. Clin Infect Dis. 2024;79(4):e27-e47. doi: 10.1093/cid/ciae421. PubMed PMID: 39405483.

139. World Health Organization. The End-TB Strategy. Geneva, Switzerland: 2014.

140. Salindri AD, Kipiani M, Lomtadze N, Tukvadze N, Avaliani Z, Blumberg HM, Masyn KE, Rothenberg RB, Kempker RR, Magee MJ. HIV co-infection increases the risk of post-tuberculosis mortality among persons who initiated treatment for drug-resistant tuberculosis. Sci Rep. 2024;14(1):23834. doi: 10.1038/s41598-024-68605-2. PubMed PMID: 39394335; PMCID: PMC11470076.

141. Allwood BW, Nightingale R, Agbota G, Auld S, Bisson GP, Byrne A, Dunn R, Evans D, Hoddinott G, Gunther G, Islam Z, Johnston JC, Kalyatanda G, Khosa C, Marais S, Makanda G, Mashedi OM, Meghji J, Mitnick C, Mulder C, Nkereuwem E, Nkereuwem O, Ozoh OB, Rachow A, Romanowski K, Seddon JA, Schoeman I, Thienemann F, Walker NF, Wademan DT, Wallis R, van der Zalm MM. Perspectives from the 2(nd) International Post-Tuberculosis Symposium: mobilising advocacy and research for improved outcomes. IJTLD Open. 2024;1(3):111-23. doi: 10.5588/ijtldopen.23.0619. PubMed PMID: 38966406; PMCID: PMC11221578.

142. Auld SC, Barczak AK, Bishai W, Coussens AK, Dewi IMW, Mitini-Nkhoma SC, Muefong C, Naidoo T, Pooran A, Stek C, Steyn AJC, Tezera L, Walker NF. Pathogenesis of Post-Tuberculosis Lung Disease: Defining Knowledge Gaps and Research Priorities at the Second International Post-Tuberculosis Symposium. Am J Respir Crit Care Med. 2024;210(8):979-93. doi: 10.1164/rccm.202402-0374SO. PubMed PMID: 39141569; PMCID: PMC11531093.

143. Mbanje C, Kuhn I, Musakwa N, Calvi M, Boccia D, Muhwa JC, Mvusi L, Jaramillo E, Evans D, Meghji J. A scoping review of interventions to address TB associated respiratory disability. EClinicalMedicine. 2024;73:102646. doi: 10.1016/j.eclinm.2024.102646. PubMed PMID: 38846067; PMCID: PMC11154123.

144. Nkereuwem E, Ageiwaa Owusu S, Fabian Edem V, Kampmann B, Togun T. Post-tuberculosis lung disease in children and adolescents: A scoping review of definitions, measuring tools, and research gaps. Paediatr Respir Rev. 2024. doi: 10.1016/j.prrv.2024.07.001. PubMed PMID: 39129097.

145. Byrne A, Allwood B, Schoeman I, Johnston J, Kalyatanda G, Makanda G, Mortimer K, Mitnick C, Nightingale R, Ozoh O, Rachow A, Van Der Zalm M. “Post tuberculosis”: the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials. Eur Respir J. 2023;62(3). doi: 10.1183/13993003.00950-2023. PubMed PMID: 37690787; PMCID: PMC10492662.

146. Wallis RS, Sabi I, Lalashowi J, Bakuli A, Mapamba D, Olomi W, Siyame E, Ngaraguza B, Chimbe O, Charalambous S, Rachow A, Ivanova O, Zurba L, Myombe B, Kunambi R, Hoelscher M, Ntinginya N, Churchyard G. Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis. NEJM Evid. 2024;3(9):EVIDoa2300332. doi: 10.1056/EVIDoa2300332. PubMed PMID: 39189858.

147. Hussain A, Khurana AK, Goyal A, Kothari SY, Soman RK, Tej S, Pakhare A. Effect of pulmonary rehabilitation in patients with post-tuberculosis sequelae with functional limitation. Indian J Tuberc. 2024;71(2):123-9. doi: 10.1016/j.ijtb.2023.04.012. PubMed PMID: 38589115.

148. Kharwadkar S, Attanayake V, Duncan J, Navaratne N, Benson J. The impact of climate change on the risk factors for tuberculosis: A systematic review. Environ Res. 2022;212(Pt C):113436. doi: 10.1016/j.envres.2022.113436. PubMed PMID: 35550808.

149. Charlton J. Nothing About Us Without Us: Disability Oppression and Empowerment. Oakland, CA, USA: University of California Press; 1998.

150. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment, second edition. CC BY-NC-SA 3.0 IGO. Geneva, Switzerland: 2024.

151. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection, third edition. CC BY-NC-SA 3.0 IGO. Geneva, Switzerland: 2024.

152. World Health Organization. Diagnosis of tuberculosis and detection of drug-resistance rapid communication. . Geneva, Switzerland: 2024.

153. World Health Organization. Co-administration of treatment for drug-resistant tuberculosis and hepatitis C. Rapid Communication. Geneva, Switzerland: 2024.

154. Auer C, Gupta A, Malbacius C, Ghafoor A, Kock Y, Medvedieva O, Hanlon P, Steinmann P, Juneja S. Savings from the introduction of BPaL and BPaLM regimens at the country level. IJTLD Open. 2024;1(7):314-9. doi: 10.5588/ijtldopen.24.0213. PubMed PMID: 39035434; PMCID: PMC11257096.

155. Khan MA, Ismail A, Ghafoor A, Khan N, Muzaffar N, Zafar F, Gupta A, Foraida S, Juneja S, Fatima R, Khan AW, Shahid S, Khan MA. Experience of piloting BPaLM/BPaL for DR-TB care at selected sites in Pakistan. IJTLD Open. 2024;1(11):508-15. doi: 10.5588/ijtldopen.24.0369. PubMed PMID: 39544887; PMCID: PMC11558782.

156. Wares DF, Mbenga M, Mirtskhulava V, Quelapio M, Slyzkyi A, Koppelaar I, Cho SN, Go U, Lee JS, Jung JK, Everitt D, Foraida S, Diachenko M, Juneja S, Burhan E, Totkogonova A, Myint Z, Flores I, Lytvynenko NA, Parpieva N, Nhung NV, Gebhard A. Introducing BPaL: Experiences from countries supported under the LIFT-TB project. PLoS One. 2024;19(11):e0310773. doi: 10.1371/journal.pone.0310773. PubMed PMID: 39561206; PMCID: PMC11575791.

157. Barilar I, Fernando T, Utpatel C, Abujate C, Madeira CM, Jose B, Mutaquiha C, Kranzer K, Niemann T, Ismael N, de Araujo L, Wirth T, Niemann S, Viegas S. Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB/RIF in Mozambique: a retrospective observational study. Lancet Infect Dis. 2024;24(3):297-307. doi: 10.1016/S1473-3099(23)00498-X. PubMed PMID: 37956677.

158. Derendinger B, Dippenaar A, de Vos M, Huo S, Alberts R, Tadokera R, Limberis J, Sirgel F, Dolby T, Spies C, Reuter A, Folkerts M, Allender C, Lemmer D, Van Rie A, Gagneux S, Rigouts L, Te Riele J, Dheda K, Engelthaler DM, Warren R, Metcalfe J, Cox H, Theron G. Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study. Lancet Microbe. 2023;4(12):e972-e82. doi: 10.1016/S2666-5247(23)00172-6. PubMed PMID: 37931638; PMCID: PMC10842724.

159. Ness T, Van LH, Petermane I, Duarte R, Lange C, Menzies D, Cirillo DM. Rolling out new anti-tuberculosis drugs without diagnostic capacity. Breathe (Sheff). 2023;19(2):230084. doi: 10.1183/20734735.0084-2023. PubMed PMID: 37492347; PMCID: PMC10365078.

160. Padmapriyadarsini C, Oswal VS, Jain CD, Mariappan MV, Singla N, Kumar S, Daniel BD, Dave JD, Vadgama P, Ramraj B, Kant S, Bhatnagar AK, Shanmugam S, Paul D, Bharathi J, Palav M, Shah NV, Santhanakrishnan R, Dewan RK, Shekh N, Rathinam P, Sisara AB, Mankar SD, Bajpai J, Mittal U, Chauhan S, Kumar R, Parmar M, Mattoo SK, Jaju J, modified BST. Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial. Clin Infect Dis. 2024;79(6):1375-85. doi: 10.1093/cid/ciae388. PubMed PMID: 39194339.

161. Zielinski N, Baiceanu D, Dragomir A, Heyckendorf J, Ibraim E, Kohler N, Leschczyk C, Popa C, Rachow A, Sachsenweger J, Sanchez Carballo P, Schaub D, Zeeb H, Tulu B, DiNardo AR, Lange C, Reimann M. A Transcriptomic Biomarker Predicting Linezolid-Associated Neuropathy During Treatment of Drug-Resistant Tuberculosis. Pathog Immun. 2024;9(2):25-42. doi: 10.20411/pai.v9i2.705. PubMed PMID: 38939039; PMCID: PMC11210591.

Most read articles by the same author(s)